Amgen (AMGN) May See Pressure as TYK2 Emerges as a Legitimate Contender to Otezla - SVB Leerink
Tweet Send to a Friend
SVB Leerink analyst Geoffrey Porges reiterated a Market Perform rating on Amgen (NASDAQ: AMGN) after Bristol-Myers Squibb (NYSE: BMY) reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
